Meyka Pro banner
Neuronetics, Inc.

Neuronetics, Inc. Fundamental Analysis (NASDAQ: STIM)

STIM●NASDAQ
HealthcareMedical - Devices
$1.43
$0.58(29.02%)
U.S. Market is Open · 13:35

Neuronetics, Inc. Fundamental Analysis (NASDAQ: STIM)

Neuronetics, Inc. (NASDAQ: STIM) shows moderate financial fundamentals with a PE ratio of -5.10, profit margin of -14.45%, and ROE of -1.28%. The company generates $0.2B in annual revenue with strong year-over-year growth of 99.17%.

Key Strengths

Cash Position17.59%
PEG Ratio-0.05
Current Ratio2.01

Areas of Concern

ROE-1.28%
Operating Margin-9.39%
We analyze STIM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -108.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-108.9/100

We analyze STIM's fundamental strength across five key dimensions:

Efficiency Score

Weak

STIM struggles to generate sufficient returns from assets.

ROA > 10%
-17.49%

Valuation Score

Excellent

STIM trades at attractive valuation levels.

PE < 25
-5.10
PEG Ratio < 2
-0.05

Growth Score

Excellent

STIM delivers strong and consistent growth momentum.

Revenue Growth > 5%
99.17%
EPS Growth > 10%
57.25%

Financial Health Score

Moderate

STIM shows balanced financial health with some risks.

Debt/Equity < 1
4.69
Current Ratio > 1
2.01

Profitability Score

Weak

STIM struggles to sustain strong margins.

ROE > 15%
-127.86%
Net Margin ≥ 15%
-14.45%
Positive Free Cash Flow
No

Key Financial Metrics

Is STIM Expensive or Cheap?

P/E Ratio

STIM trades at -5.10 times earnings. This suggests potential undervaluation.

-5.10

PEG Ratio

When adjusting for growth, STIM's PEG of -0.05 indicates potential undervaluation.

-0.05

Price to Book

The market values Neuronetics, Inc. at 6.76 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.76

EV/EBITDA

Enterprise value stands at -5.14 times EBITDA. This is generally considered low.

-5.14

How Well Does STIM Make Money?

Net Profit Margin

For every $100 in sales, Neuronetics, Inc. keeps $-14.45 as profit after all expenses.

-14.45%

Operating Margin

Core operations generate -9.39 in profit for every $100 in revenue, before interest and taxes.

-9.39%

ROE

Management delivers $-1.28 in profit for every $100 of shareholder equity.

-1.28%

ROA

Neuronetics, Inc. generates $-17.49 in profit for every $100 in assets, demonstrating efficient asset deployment.

-17.49%

Following the Money - Real Cash Generation

Operating Cash Flow

Neuronetics, Inc. generates limited operating cash flow of $-7.03M, signaling weaker underlying cash strength.

$-7.03M

Free Cash Flow

Neuronetics, Inc. generates weak or negative free cash flow of $-8.32M, restricting financial flexibility.

$-8.32M

FCF Per Share

Each share generates $-0.11 in free cash annually.

$-0.11

FCF Yield

STIM converts -6.76% of its market value into free cash.

-6.76%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.10

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.05

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.76

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.80

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.69

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.007

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.28

vs 25 benchmark

ROA

Return on assets percentage

-0.17

vs 25 benchmark

ROCE

Return on capital employed

-0.14

vs 25 benchmark

How STIM Stacks Against Its Sector Peers

MetricSTIM ValueSector AveragePerformance
P/E Ratio-5.1031.66 Better (Cheaper)
ROE-127.86%501.00% Weak
Net Margin-14.45%-3647.00% (disorted) Weak
Debt/Equity4.69-0.30 (disorted) Distorted
Current Ratio2.015.78 Strong Liquidity
ROA-17.49%-262.00% (disorted) Weak

STIM outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Neuronetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-13.50%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

59.43%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

79.50%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ